China's willingness to get aggressive in protecting biopharma's intellectual property is being credited with its surge past India in the total number of completed and ongoing clinical trials. An Indian court's ruling against Novartis on Gleevec is helping accelerate a trend away from the subcontinent. There's no sign that India's generic drug industry is flagging, though, with homegrown companies aggressively going after new markets--including biosimilars. We may be seeing a trend here that will take China forward as a new base for drug discovery work based on high quality and low costs while India sees generics grow ever stronger.
- here's the research from Seeking Alpha
ALSO: China's generics industry is gearing up for an onslaught on the U.S. market. Report
Related Articles:
China now leads India in ongoing clinical trials. Report
China's pharma market steams ahead. Report
China pushes drug development as R&D soars. Report
China to overhaul drug safety regulations. Report
Bridge Pharma sees growth in China drug studies. Report